Cas:383365-04-6 Tenofovir alafenamide manufacturer & supplier

Chemical Name:Tenofovir alafenamide

CAS.NO:383365-04-6

Synonyms:9-[(R)-2-[[(R)-[[(S)-1-(isopropoxycarbonyl)ethyl]amino](phenoxy)phosphinyl]methoxy]propyl]adenine;Isopropyl N-[(S)-({[(2R)-1-(6-amino-9H-purin-9-yl)-2-propanyl]oxy}methyl)(phenoxy)phosphoryl]-L-alaninate;L-Alanine, N-[(S)-[(1S)-[(1R)-2-(6-amino-9H-purin-9-yl)-1-methylethoxy]methyl]phenoxyphosphinyl]-, 1-methylethyl ester;Tenofovir Related Compound 6;Tenofovir alafenamide

Molecular Formula:C₂₁H₂₉N₆O₅P

Molecular Weight:476.466

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:640.4±65.0 °C at 760 mmHg

Density:1.4±0.1 g/cm3

Index of Refraction:1.630

PSA:153.29000

Exact Mass:476.193695

LogP:2.20

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 9-[(R)-2-[[(R)-[[(S)-1-(isopropoxycarbonyl)ethyl]amino](phenoxy)phosphinyl]methoxy]propyl]adenine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Tenofovir alafenamide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,9-[(R)-2-[[(R)-[[(S)-1-(isopropoxycarbonyl)ethyl]amino](phenoxy)phosphinyl]methoxy]propyl]adenine Use and application,Tenofovir alafenamide technical grade,usp/ep/jp grade.

Related News: Today’s decisions represent progress in our continued efforts to make a difference in this pandemic on a global scale, Kathy Wengel, J&J’s chief global supply chain officer, said in the statement. Tenofovir alafenamide manufacturer As the first-to-market BTK inhibitor, Imbruvica has been treating front-line CLL patients since its monotherapy go-ahead in early 2016. But it’s now facing competition from AstraZeneca’s Calquence, which just detailed a head-to-head safety advantage over Imbruvica in previously treated CLL. Tenofovir alafenamide supplier China is fast-tracking approval for innovative drugs at home in a bid to offer more and cheaper options to patients, as many in the rapidly aging country struggle to find alternatives to costly treatments sold by multinational pharmaceutical firms for chronic diseases. Tenofovir alafenamide vendor As the first-to-market BTK inhibitor, Imbruvica has been treating front-line CLL patients since its monotherapy go-ahead in early 2016. But it’s now facing competition from AstraZeneca’s Calquence, which just detailed a head-to-head safety advantage over Imbruvica in previously treated CLL. Tenofovir alafenamide factory Today’s decisions represent progress in our continued efforts to make a difference in this pandemic on a global scale, Kathy Wengel, J&J’s chief global supply chain officer, said in the statement.